Skip to main content

Table 1 Single agent clinical trials of venetoclax/ABT-199

From: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Clinical trials Diseases Responses References
Phase I R/R CLL ORR—79 % 81, 83
Phase Ia R/R NHL ORR—48 % 84
Phase II R/R AML ORR—15 % 85
New AML
  1. R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia